Lincoln Capital Corp Akebia Therapeutics, Inc. Transaction History

Lincoln Capital Corp

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Jul 22, 2021	SELL	$2.83 - $4.2 $45,766 - $67,922	-16,172 Closed	0 $0
Q1 2021 Apr 20, 2021	SELL	$2.92 - $5.06 $14,570 - $25,249	-4,990 Reduced 23.58%	16,172 $55,000
Q3 2020 Nov 04, 2020	BUY	$2.39 - $13.08 $12,313 - $67,388	5,152 Added 32.18%	21,162 $53,000
Q2 2020 Jul 22, 2020	SELL	$6.67 - $13.58 $51,732 - $105,326	-7,756 Reduced 32.63%	16,010 $217,000
Q4 2019 Jan 17, 2020	BUY	$3.16 - $6.73 $10,270 - $21,872	3,250 Added 15.84%	23,766 $150,000
Q3 2019 Nov 05, 2019	BUY	$3.55 - $5.4 $862 - $1,312	243 Added 1.2%	20,516 $80,000
Q2 2019 Jul 12, 2019	SELL	$4.1 - $8.05 $5,883 - $11,551	-1,435 Reduced 6.61%	20,273 $98,000
Q4 2018 Jan 22, 2019	BUY	$5.39 - $9.15 $117,006 - $198,628	21,708 New	21,708 $120,000

128

63.3M

50.6K

203K

Ticker AKBA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 183,848,992
Market Cap $364M
Description
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...

Get notified when there are updates to the investment portfolio of Lincoln Capital Corp, based on Form 13F filings with the SEC.

Stay updated on Lincoln Capital Corp with notifications on news.